Cardiol Therapeutics (CRDL) Non-Current Assets (2020 - 2026)

Cardiol Therapeutics has reported Non-Current Assets for 7 years, with the latest figure at $101337.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 20.34% year-over-year to $101337.0; the trailing twelve-month figure through Mar 2026 stood at $406471.7 (down 46.3% YoY), and the FY2025 full-year result was $84682.9, down 39.52% from the prior year.
• Non-Current Assets for Q1 2026 stood at $101337.0, up from $84682.9 in the prior quarter.
• The five-year high for Non-Current Assets was $550723.8 in Q1 2022, with the low at $84682.9 in Q4 2025.
• Historically, Non-Current Assets has averaged $302742.1 across 5 years, with a median of $363081.1 in 2024.
• Annual changes were most pronounced in 2023 — Non-Current Assets fell 2.27% — and 2024, when it tumbled 65.18%.
• Cardiol Therapeutics' Non-Current Assets stood at $435052.6 in 2022, then retreated by 7.58% to $402096.5 in 2023, then plunged by 65.18% to $140014.4 in 2024, then tumbled by 39.52% to $84682.9 in 2025, then grew by 19.67% to $101337.0 in 2026.
• The last three Non-Current Assets figures came in at $101337.0 (Q1 2026), $84682.9 (Q4 2025), and $102441.7 (Q3 2025), per Business Quant data.